Full-Time

Strategic Account Manager

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$152k - $202k/yr

+ Annual short-term incentive + Annual long-term incentive + Bonus or sales incentive + Equity

Los Angeles, CA, USA

Remote

Must live within the stated territory; travel up to 100% within the geography is required.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
CRM

Get referred to Invivyd

See people who can refer or advise you

Requirements
  • Candidates without a degree may be considered if they have significant relevant, related industry experience.
  • Must hold a current, valid state driver's license and pass a motor vehicle record background check.
  • Candidates must live within the stated territory.
  • Ability to travel up to 100% within the geography, including driving and/or flying within the territory.
  • Must work in the field five days a week while completing administrative tasks related to the role.
  • Proven track record of consistent high performance and successfully selling to large accounts and key customer segments.
  • Ability to communicate compliant clinical product information.
  • Diverse experience in a matrixed environment and exposure to reimbursement, buy-and-bill, specialty pharmacies, integrated delivery networks, and federal channels.
  • Strong understanding of the laws, regulations, and industry codes governing interactions with healthcare professionals and healthcare organizations, including the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals.
  • Knowledge of the Veterans Affairs system within the territory and the rules and regulations for conducting business within that system.
  • Results-oriented approach and demonstrated time management skills.
  • Broad understanding and experience with case management, market access, reimbursement, and selling a medical benefit product.
  • Experience working with hematology/oncology, rheumatology, transplant, hospital/integrated delivery network, Veterans Affairs, and immunology accounts, as well as account management strategy and new product launches.
  • Effective time management, organizational, and interpersonal skills to prioritize opportunities.
  • Proven sales performance demonstrated by consistently exceeding quotas, Presidents Club wins, or other awards.
Responsibilities
  • Provide solutions to customers by acting as a key business owner of company resources and solutions for healthcare providers, healthcare organizations, centers of excellence, integrated delivery network stakeholders, Veterans Affairs centers, reimbursement personnel, and practice administrators, while collaborating to resolve customer inquiries.
  • Facilitate clinical dialogue that motivates customers to act on behalf of patients and engage the entire account to identify obstacles and provide appropriate solutions.
  • Identify shared priorities and use account knowledge and tactics to develop a strategic territory business plan that drives product demand and meets the needs of key partners and patients.
  • Collaborate with cross-functional partners on account and territory strategy to maximize internal and external knowledge of product and service access.
  • Aggregate customer and market data and insights to apply multiple channels to drive total selling engagements.
  • Use a data-driven approach to prioritize customers and accounts in alignment with the strategic plan.
Desired Qualifications
  • A minimum of 10 years of sales experience in the biopharmaceutical industry is preferred.
  • A bachelor's degree is strongly preferred.

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Invivyd

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 PEMGARDA revenue reached $13.7 million, up 22% year over year.
  • Invivyd ended Q1 2026 with $184.2 million cash, plus $20 million April ATM proceeds.
  • June 2026 enrollment completion in DECLARATION and LIBERTY de-risk near-term clinical catalysts.

What critics are saying

  • FDA terminated PEMGARDA's EUA effective June 29, 2027, shrinking commercial runway.
  • DECLARATION and LIBERTY still need positive Q3 2026 data; failure kills VYD2311.
  • The ADG20 securities case remains pending, keeping litigation overhang and reputational damage alive.

What makes Invivyd unique

  • PEMGARDA gives Invivyd a commercial foothold in immunocompromised COVID prophylaxis.
  • VYD2311 targets vaccine-alternative prophylaxis with Phase 3 DECLARATION and LIBERTY data in Q3 2026.
  • Fast Track status from FDA and IM dosing support a differentiated execution path.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
May 18th, 2026
Invivyd reports $13.7M Q1 revenue, 22% growth, advances COVID-19 monoclonal antibody trial

Invivyd Inc. reported first-quarter earnings on 14 May, with PEMGARDA net product revenue reaching $13.7 million, up 22% year-on-year. The biopharmaceutical company ended the quarter with $184.2 million in cash, supplemented by approximately $20 million from an at-the-market offering in April. The company posted a net loss of $41.4 million, driven by increased operating expenses related to its DECLARATION Phase 3 clinical trial for VYD2311, a COVID-19 monoclonal antibody candidate. The trial achieved initial full enrollment in March, with top-line data now expected in the third quarter. Invivyd is preparing additional Phase 3 trials and advancing its pipeline beyond COVID-19, including VMS063 for measles and VBY329 for paediatric respiratory syncytial virus prophylaxis.

Yahoo Finance
May 14th, 2026
Invivyd reports 22% YoY PEMGARDA revenue growth amid clinical trial investments

Invivyd Inc reported strong revenue growth in its Q1 2026 earnings call, with monoclonal antibody revenues continuing to grow and PEMGARDA revenue increasing 22% year-over-year compared to Q1 2025. The company accelerated recruitment for its pivotal DECLARATION trial, exceeding internal expectations, though recruitment slowed during a lull in COVID-19 cases. The company confirmed virus neutralisation against the Omicron BA.3.2 variant and is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella and Lyme disease. Invivyd reported significant clinical spending on the DECLARATION trial but expects R&D spending to normalise as the VYD2311 trial concludes. The company strengthened its cash position through additional funding raised in April and received positive feedback from policymakers on increased government affairs activity.

Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.